Developer docs
API playgroundTry for free, no card

Search company profiles

Apyx Medical

Full company profile

uuid0002pox

Namestring
Apyx Medical
Legal namestring
Apyx Medical Corporation
Websiteurl
apyxmedical.com
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Apyx Medical Corporation is a publicly traded medical device company (NASDAQ: APYX) headquartered in Clearwater, Florida, that designs and manufactures energy-based surgical systems for the cosmetic and hospital surgical markets. The company's proprietary Helium Plasma Platform Technology combines helium plasma with radiofrequency (RF) energy to deliver controlled tissue heating to approximately 85°C, enabling soft tissue contraction, collagen production, and tissue remodeling. This platform underpins three product lines: Renuvion (cosmetic and aesthetic surgery), J-Plasma (hospital-based electrosurgical cutting, coagulation, and ablation), and the AYON Body Contouring System (the first FDA-cleared all-in-one body contouring platform, commercially launched in the U.S. in September 2025 after May 2025 FDA clearance). Renuvion is the only FDA-cleared device indicated for use after liposuction, improving loose skin on the neck and chin, and contracting subcutaneous soft tissue anywhere on the body.

The company's commercial model combines capital equipment sales (Renuvion, AYON, and Apyx One generators) with a recurring single-use handpiece revenue stream per procedure. Apyx sells primarily through a direct enterprise field sales force targeting board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments, supplemented by KOL events, clinical symposia, consumer-facing initiatives (such as the Miami Swim Week showcase), and a 'Find a Provider' patient referral system. Revenue is generated across three streams: Surgical Aesthetics (Renuvion and AYON products), Hospital Surgical (J-Plasma), and OEM agreements (including a 10-year generator manufacturing and supply agreement with Symmetry Surgical). The company has been expanding internationally with commercial launches in South Korea (Q4 2025) and China (July 2025), and has received multiple FDA 510(k) clearances including the May 2026 expanded indication adding power liposuction to AYON.

For the 2025 fiscal year, Apyx reported preliminary revenue of approximately $52.8M, with Q4 2025 revenue of $19.2M representing 34% year-over-year growth. Q1 2026 revenue of $12.5M grew 33% year-over-year, with the Surgical Aesthetics segment up 36% and gross margin expanding to 63.5%. The company holds a $31.1M cash position providing runway through 2027, supported by debt facilities with Perceptive Advisors ($45M, 2023) and MidCap Financial ($35M, 2023), as well as a $10M public equity offering completed in November 2025. FY2026 revenue guidance has been raised to $59-60M.

Short descriptiontext

Apyx Medical Corporation (NASDAQ: APYX) designs and manufactures energy-based surgical systems, including the Renuvion helium plasma platform, J-Plasma, and the AYON all-in-one body contouring system, serving board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersClearwater, United States
HQ citystring
Clearwater
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
surgical energy devices, body contouring systems, helium plasma technology, electrosurgical generators, soft tissue contraction
Industry1 code
PRIMARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Surgical Energy Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Surgical Aesthetics Products
TypeHardware Sales
Description

Revenue from sale of Renuvion and AYON generators and single-use handpieces to surgeons and surgical centers. Single-use handpieces represent recurring consumable revenue as procedures are performed. Includes domestic U.S. and international sales.

apyxmedical.com
2OEM Agreements
TypeLicensing Royalties
Description

Leverages deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. Symmetry Surgical agreement mentioned for generator manufacturing and supply.

apyxmedical.com
3J-Plasma Hospital Surgical Products
TypeHardware Sales
Description

Revenue from J-Plasma products for hospital surgical market, offering surgeons controlled heat delivery for electrosurgical cutting, coagulation and ablation of soft tissue during open surgical procedures.

apyxmedical.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Renuvion
Description

Helium Plasma Platform Technology for soft tissue contraction in cosmetic surgery; FDA-cleared device for use after liposuction and for improving loose skin on neck and chin; #1 trusted body contouring technology among plastic surgeons

apyxmedical.com
+3 more records
Core offering1 text field

Apyx Medical Corporation designs, manufactures, and sells energy-based medical devices built on its proprietary Helium Plasma Platform Technology. Its core products are the Renuvion helium plasma + radiofrequency generators and single-use handpieces, the AYON Body Contouring System, and J-Plasma generators, sold to board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments for soft tissue contraction, body contouring, and electrosurgical cutting/coagulation/ablation procedures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 81.8% of patients showed improvement in cellulitis appearance at 180 days when Renuvion paired with Avéli
+4 more records
Product overview1 text field

Apyx Medical offers a portfolio of energy-based medical devices centered on its proprietary Helium Plasma Platform Technology. The core product family includes Renuvion (for cosmetic surgery), J-Plasma (for hospital surgical procedures), and the AYON Body Contouring System (an all-in-one platform). Renuvion provides helium plasma and RF tissue contraction using a unique combination of helium gas and radiofrequency energy. The AYON System integrates Renuvion technology with multiple body contouring modalities including ultrasound-assisted liposuction, power-assisted liposuction, electrosurgery, dual aspiration, and infiltration into a unified platform. The company also leverages its technology through OEM agreements with other medical device manufacturers and sells the Apyx One Console system. Renuvion is the only FDA-cleared device for post-liposuction tissue contraction, neck/chin skin tightening, and subcutaneous soft tissue contraction.

Product and service5 records
1Renuvion
CategoryEnergy-based aesthetic device
Description

Helium plasma and radiofrequency generator and single-use handpieces for plastic and cosmetic surgeons that heat subdermal tissue to approximately 85°C to contract soft tissue, tighten skin, and stimulate collagen. The only FDA-cleared device for use after liposuction, for improving loose skin on the neck and chin, and for contracting subcutaneous soft tissue anywhere on the body. Supported by 90+ clinical papers.

2AYON Body Contouring System
CategoryIntegrated body contouring system
Description

First FDA-cleared all-in-one body contouring system that integrates advanced ultrasound-assisted liposuction, power liposuction, Renuvion tissue contraction, electrosurgical capabilities, dual aspiration, infiltration, and closed-loop contouring into a single platform. Features Smart LIFT technology for real-time energy adjustments. Designed for the aesthetic surgical suite.

3J-Plasma
CategoryElectrosurgical device
Description

Helium plasma-based generator and handpieces for hospital surgical departments that deliver controlled heat to soft tissue for electrosurgical cutting, coagulation, and ablation during open surgical procedures.

4Apyx One Console
CategoryGenerator platform
Description

Generator console and single-use handpieces for cosmetic surgical procedures, including the APYX-JS3, APYX-RS3, and APYX-ONE generator units. Approved for commercial launch in South Korea targeting the cosmetic surgery market.

5OEM Manufacturing and Waveform Licensing
CategoryOEM and licensing
Description

OEM agreements under which Apyx Medical licenses its proprietary waveform technology and manufactures generators for other medical device companies, leveraging decades of expertise in unique energy waveforms (e.g., Symmetry Surgical generator manufacturing and supply agreement).

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-21
Description

Clinical collaboration evaluating combination treatment using Avéli for targeted subcision to disrupt fibrous septae, followed by Renuvion for skin laxity reduction through controlled helium plasma radiofrequency energy. Study published in Aesthetic Surgery Journal Open Forum showing 81.8% patient improvement at 180 days.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

10-year generator manufacturing and supply agreement under Apyx Medical's OEM business segment. Symmetry Surgical manufactures and supplies generators using Apyx's unique waveform technology.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

InMode develops and markets energy-based aesthetic devices for body contouring, skin tightening, and facial aesthetics. It directly competes with Apyx's Renuvion in minimally invasive tissue contraction and shares the same surgeon customer base.

2BTL Industries
TypeDirect peer
Description

BTL markets EMSCULPT, EMSELLA, and other non-invasive body contouring and aesthetic platforms. It competes with Renuvion and AYON for the same plastic surgeon and medspa accounts pursuing body shaping and skin tightening procedures.

TypeDirect peer
Description

Cutera manufactures laser and energy-based aesthetic systems for skin rejuvenation, body contouring, and vascular lesions. It overlaps with Apyx's surgeon-facing aesthetic channel and competes for capital equipment budgets in dermatology and plastic surgery practices.

TypeDirect peer
Description

Cynosure offers a broad portfolio of aesthetic energy devices (lasers, RF, body contouring). It competes with both Renuvion and AYON in plastic surgery and aesthetic medicine channels.

TypeDirect peer
Description

Solta markets Thermage (RF-based skin tightening) and other aesthetic systems. Its Thermage franchise is the closest direct substitute to Renuvion's skin tightening indication.

TypeEmerging player
Description

Venus Concept markets energy-based aesthetic devices (Venus Bliss, Venus Legacy) targeting body contouring and skin tightening. It overlaps with Apyx's surgical aesthetics segment with a focus on minimally invasive procedures.

7Sciton
TypeEmerging player
Description

Sciton produces aesthetic and medical laser/light platforms used by plastic surgeons and dermatologists. Its portfolio overlaps with Renuvion's physician channel, particularly in skin rejuvenation and tightening.

TypeBroad incumbent
Description

Conmed manufactures electrosurgical generators and instruments for hospital surgical markets, directly comparable to Apyx's J-Plasma legacy hospital business. It is a much larger diversified medtech player serving similar surgical energy buyers.

TypeBroad incumbent
Description

Olympus has a substantial surgical energy portfolio (acquired from Gyrus ACMI) overlapping with J-Plasma in hospital electrosurgery. Apyx CEO Charles Goodwin previously held commercial leadership roles at Olympus/Gyrus.

TypeBroad incumbent
Description

Stryker's surgical equipment segment includes electrosurgical and energy-based devices for hospital ORs, comparable to J-Plasma's hospital surgical market. It is a much larger diversified incumbent in the same buyer accounts.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Apyx Medical

Surgical Energy Devicesapyxmedical.com

Apyx Medical Corporation (NASDAQ: APYX) designs and manufactures energy-based surgical systems, including the Renuvion helium plasma platform, J-Plasma, and the AYON all-in-one body contouring system, serving board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments.

What Apyx Medical does

Apyx Medical Corporation is a publicly traded medical device company (NASDAQ: APYX) headquartered in Clearwater, Florida, that designs and manufactures energy-based surgical systems for the cosmetic and hospital surgical markets. The company's proprietary Helium Plasma Platform Technology combines helium plasma with radiofrequency (RF) energy to deliver controlled tissue heating to approximately 85°C, enabling soft tissue contraction, collagen production, and tissue remodeling. This platform underpins three product lines: Renuvion (cosmetic and aesthetic surgery), J-Plasma (hospital-based electrosurgical cutting, coagulation, and ablation), and the AYON Body Contouring System (the first FDA-cleared all-in-one body contouring platform, commercially launched in the U.S. in September 2025 after May 2025 FDA clearance). Renuvion is the only FDA-cleared device indicated for use after liposuction, improving loose skin on the neck and chin, and contracting subcutaneous soft tissue anywhere on the body.

The company's commercial model combines capital equipment sales (Renuvion, AYON, and Apyx One generators) with a recurring single-use handpiece revenue stream per procedure. Apyx sells primarily through a direct enterprise field sales force targeting board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments, supplemented by KOL events, clinical symposia, consumer-facing initiatives (such as the Miami Swim Week showcase), and a 'Find a Provider' patient referral system. Revenue is generated across three streams: Surgical Aesthetics (Renuvion and AYON products), Hospital Surgical (J-Plasma), and OEM agreements (including a 10-year generator manufacturing and supply agreement with Symmetry Surgical). The company has been expanding internationally with commercial launches in South Korea (Q4 2025) and China (July 2025), and has received multiple FDA 510(k) clearances including the May 2026 expanded indication adding power liposuction to AYON.

For the 2025 fiscal year, Apyx reported preliminary revenue of approximately $52.8M, with Q4 2025 revenue of $19.2M representing 34% year-over-year growth. Q1 2026 revenue of $12.5M grew 33% year-over-year, with the Surgical Aesthetics segment up 36% and gross margin expanding to 63.5%. The company holds a $31.1M cash position providing runway through 2027, supported by debt facilities with Perceptive Advisors ($45M, 2023) and MidCap Financial ($35M, 2023), as well as a $10M public equity offering completed in November 2025. FY2026 revenue guidance has been raised to $59-60M.

Apyx Medical firmographics

Firmographics
Name
Apyx Medical
Legal name
Apyx Medical Corporation
Website
https://apyxmedical.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Apyx Medical Corporation (NASDAQ: APYX) designs and manufactures energy-based surgical systems, including the Renuvion helium plasma platform, J-Plasma, and the AYON all-in-one body contouring system, serving board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments.
Ownership category
akta.pro rank

Apyx Medical industry classification

Industry
Product category
Surgical Energy Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAC
Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment

Keywords

  • Surgical energy devices
  • Body contouring systems
  • Helium plasma technology
  • Electrosurgical generators
  • Soft tissue contraction

Where Apyx Medical is headquartered

Location

Headquarters

HQ city
Clearwater
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Apyx Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Surgical Aesthetics Products: Revenue from sale of Renuvion and AYON generators and single-use handpieces to surgeons and surgical centers. Single-use handpieces represent recurring consumable revenue as procedures are performed. Includes domestic U.S. and international sales.
  2. OEM Agreements: Leverages deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. Symmetry Surgical agreement mentioned for generator manufacturing and supply.
  3. J-Plasma Hospital Surgical Products: Revenue from J-Plasma products for hospital surgical market, offering surgeons controlled heat delivery for electrosurgical cutting, coagulation and ablation of soft tissue during open surgical procedures.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Apyx Medical product offering

Product offering

Core offering

Apyx Medical Corporation designs, manufactures, and sells energy-based medical devices built on its proprietary Helium Plasma Platform Technology. Its core products are the Renuvion helium plasma + radiofrequency generators and single-use handpieces, the AYON Body Contouring System, and J-Plasma generators, sold to board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments for soft tissue contraction, body contouring, and electrosurgical cutting/coagulation/ablation procedures.

Product overview

Apyx Medical offers a portfolio of energy-based medical devices centered on its proprietary Helium Plasma Platform Technology. The core product family includes Renuvion (for cosmetic surgery), J-Plasma (for hospital surgical procedures), and the AYON Body Contouring System (an all-in-one platform). Renuvion provides helium plasma and RF tissue contraction using a unique combination of helium gas and radiofrequency energy. The AYON System integrates Renuvion technology with multiple body contouring modalities including ultrasound-assisted liposuction, power-assisted liposuction, electrosurgery, dual aspiration, and infiltration into a unified platform. The company also leverages its technology through OEM agreements with other medical device manufacturers and sells the Apyx One Console system. Renuvion is the only FDA-cleared device for post-liposuction tissue contraction, neck/chin skin tightening, and subcutaneous soft tissue contraction.

Differentiator

Problem solved

Functional benefit

Brands

  • Renuvion: Helium Plasma Platform Technology for soft tissue contraction in cosmetic surgery; FDA-cleared device for use after liposuction and for improving loose skin on neck and chin; #1 trusted body contouring technology among plastic surgeons
  • AYON
  • J-Plasma
  • Apyx One

Products and services

  • Renuvion Helium plasma and radiofrequency generator and single-use handpieces for plastic and cosmetic surgeons that heat subdermal tissue to approximately 85°C to contract soft tissue, tighten skin, and stimulate collagen. The only FDA-cleared device for use after liposuction, for improving loose skin on the neck and chin, and for contracting subcutaneous soft tissue anywhere on the body. Supported by 90+ clinical papers.
  • AYON Body Contouring System First FDA-cleared all-in-one body contouring system that integrates advanced ultrasound-assisted liposuction, power liposuction, Renuvion tissue contraction, electrosurgical capabilities, dual aspiration, infiltration, and closed-loop contouring into a single platform. Features Smart LIFT technology for real-time energy adjustments. Designed for the aesthetic surgical suite.
  • J-Plasma Helium plasma-based generator and handpieces for hospital surgical departments that deliver controlled heat to soft tissue for electrosurgical cutting, coagulation, and ablation during open surgical procedures.
  • Apyx One Console Generator console and single-use handpieces for cosmetic surgical procedures, including the APYX-JS3, APYX-RS3, and APYX-ONE generator units. Approved for commercial launch in South Korea targeting the cosmetic surgery market.
  • OEM Manufacturing and Waveform Licensing OEM agreements under which Apyx Medical licenses its proprietary waveform technology and manufactures generators for other medical device companies, leveraging decades of expertise in unique energy waveforms (e.g., Symmetry Surgical generator manufacturing and supply agreement).

Quantifiable outcome

  • 81.8% of patients showed improvement in cellulitis appearance at 180 days when Renuvion paired with Avéli
  • +4 more outcomes

Companies that use Apyx Medical

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Apyx Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Apyx Medical partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Tiger Aesthetics Medical (Avéli)minorStrategic or Co-development Partner · 21 May 2026Clinical collaboration evaluating combination treatment using Avéli for targeted subcision to disrupt fibrous septae, followed by Renuvion for skin laxity reduction through controlled helium plasma radiofrequency energy. Study published in Aesthetic Surgery Journal Open Forum showing 81.8% patient improvement at 180 days.
  • Symmetry SurgicalminorOEM/ Whitelabel/ Licensing Partner10-year generator manufacturing and supply agreement under Apyx Medical's OEM business segment. Symmetry Surgical manufactures and supplies generators using Apyx's unique waveform technology.

Scale indicators11 records

Recent moves8 records

Expansion highlights7 records

Apyx Medical competitors and assessment

Company assessment

Direct peers

  • InMode: InMode develops and markets energy-based aesthetic devices for body contouring, skin tightening, and facial aesthetics. It directly competes with Apyx's Renuvion in minimally invasive tissue contraction and shares the same surgeon customer base.
  • BTL Industries: BTL markets EMSCULPT, EMSELLA, and other non-invasive body contouring and aesthetic platforms. It competes with Renuvion and AYON for the same plastic surgeon and medspa accounts pursuing body shaping and skin tightening procedures.
  • Cutera: Cutera manufactures laser and energy-based aesthetic systems for skin rejuvenation, body contouring, and vascular lesions. It overlaps with Apyx's surgeon-facing aesthetic channel and competes for capital equipment budgets in dermatology and plastic surgery practices.
  • Cynosure (Hologic Aesthetics): Cynosure offers a broad portfolio of aesthetic energy devices (lasers, RF, body contouring). It competes with both Renuvion and AYON in plastic surgery and aesthetic medicine channels.
  • Solta Medical (Bausch Health): Solta markets Thermage (RF-based skin tightening) and other aesthetic systems. Its Thermage franchise is the closest direct substitute to Renuvion's skin tightening indication.

Emerging players

  • Venus Concept: Venus Concept markets energy-based aesthetic devices (Venus Bliss, Venus Legacy) targeting body contouring and skin tightening. It overlaps with Apyx's surgical aesthetics segment with a focus on minimally invasive procedures.
  • Sciton: Sciton produces aesthetic and medical laser/light platforms used by plastic surgeons and dermatologists. Its portfolio overlaps with Renuvion's physician channel, particularly in skin rejuvenation and tightening.

Broad incumbents

  • Conmed: Conmed manufactures electrosurgical generators and instruments for hospital surgical markets, directly comparable to Apyx's J-Plasma legacy hospital business. It is a much larger diversified medtech player serving similar surgical energy buyers.
  • Olympus: Olympus has a substantial surgical energy portfolio (acquired from Gyrus ACMI) overlapping with J-Plasma in hospital electrosurgery. Apyx CEO Charles Goodwin previously held commercial leadership roles at Olympus/Gyrus.
  • Stryker: Stryker's surgical equipment segment includes electrosurgical and energy-based devices for hospital ORs, comparable to J-Plasma's hospital surgical market. It is a much larger diversified incumbent in the same buyer accounts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Apyx Medical social profiles

Digital presence

Apyx Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Apyx Medical leadership team

Management profile

Number of profiles

Profiles8 records

Apyx Medical funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Apyx Medical M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apyx Medical

What does Apyx Medical do?

Apyx Medical Corporation designs, manufactures, and sells energy-based medical devices built on its proprietary Helium Plasma Platform Technology. Its core products are the Renuvion helium plasma + radiofrequency generators and single-use handpieces, the AYON Body Contouring System, and J-Plasma generators, sold to board-certified plastic surgeons, cosmetic surgeons, and hospital surgical departments for soft tissue contraction, body contouring, and electrosurgical cutting/coagulation/ablation procedures.

Is Apyx Medical a public or private company?

Apyx Medical is a public company. It is classified as public and is currently operating.

When was Apyx Medical founded?

Apyx Medical was founded in 2012. It employs 101 to 250 people.

Where is Apyx Medical based?

Apyx Medical is headquartered in Clearwater, United States, in the North America region.

How does Apyx Medical make money?

Three revenue lines are on record. Surgical Aesthetics Products are the primary driver. The others are OEM Agreements and J-Plasma Hospital Surgical Products.

Who are Apyx Medical's main competitors?

Direct peers on record are InMode, BTL Industries, Cutera, Cynosure (Hologic Aesthetics) and Solta Medical (Bausch Health). Emerging players are Venus Concept and Sciton. Broad incumbents are Conmed, Olympus and Stryker.

Does Apyx Medical have an API?

No public API is recorded for Apyx Medical.

What industry is Apyx Medical in?

Apyx Medical's product category is Surgical Energy Devices. Its primary akta.pro industry code is HLAHADAC, Energy-Based Surgical Devices (Electrosurgery, RF, Ultrasonic, Laser). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAPYX: GLP-1 demand and AYON expansion underpin 2026 revenue guidance of $59M-$60MAPYX issued 2026 revenue guidance of $59M-$60M, driven by GLP-1 demand for surgical body contouring and skin tightening. The company's AYON platform is now complete in the U.S., with margins projected at 63%-65%.Seeking AlphaApyx Medical Corporation (APYX) Presents at 2026 UBS Global Healthcare Conference TranscriptApyx Medical CEO Charles Goodwin presented at the 2026 UBS Global Healthcare Conference, detailing the company's transformation from Bovie Medical to a surgical aesthetics firm. He highlighted the AYON body contouring solution, which combines liposuction, fat transfer, and Renuvion skin tightening, and noted completion of a power-assisted handpiece for the second liposuction form.Investing.comApyx Medical at UBS global healthcare conference: sees GLP-1 tailwindApyx Medical outlined a growth plan at the UBS Global Healthcare Conference, citing GLP-1 weight-loss drugs as a major market disruption. The company expects about $54 million in revenue this year, with recurring Renuvion handpiece sales accounting for roughly half. Management sees AYON's rollout and international expansion as key growth drivers.Seeking AlphaApyx reaffirms 2026 revenue guidance of $59M-$60M while tightening operating expense target to $41M-$42.5M (NASDAQ:APYX)Apyx Medical reported Q3 2026 revenue of $14 million, up 9% year-over-year, driven by U.S. AYON and OUS Renuvion sales. The company reaffirmed full-year revenue guidance of $59–60 million, raised gross margin expectations to 63–64%, and tightened operating expense targets to $41–42.5 million. Management cited trailing 12-month positive EBITDA and ongoing OEM segment decline.MarketBeatApyx Medical Q3 Earnings Call HighlightsApyx Medical reported Q3 2026 revenue of $14 million, up 9% year-over-year, with net loss narrowing to $1.8 million. The company reaffirmed its full-year revenue guidance of $59–60 million and tightened operating expense expectations. It also highlighted a prospective Renuvion study showing improved skin quality.YahooApyx Medical (APYX) Reports Q3 Loss, Tops Revenue EstimatesApyx Medical reported a Q3 loss of $0.04 per share, beating the consensus estimate of $0.07, and posted revenue of $14.03 million, up 2.94% from the prior quarter. The company has topped consensus EPS estimates three times in the last four quarters. Management's commentary will influence near-term stock movement.Business & FinancialApyx Medical Corporation Reports Third Quarter 2026 Financial ResultsApyx Medical reported Q3 2026 revenue of $14.0 million, up 9% year-over-year, with a net loss of $1.8 million. Surgical Aesthetics sales rose 17% to $13.0 million, while OEM sales fell 42% to $1.1 million. The company reaffirmed full-year revenue guidance of $59.0–60.0 million.American Banking and Market NewsApyx Medical (APYX) Projected to Post Earnings on ThursdayApyx Medical is projected to report Q3 2026 earnings on Thursday, November 5th, with analysts expecting a loss of $0.07 per share and revenue of $13.29 million. The company's stock opened at $2.60, and analysts have set a consensus price target of $6.50.MarketBeatApyx Medical (APYX) Expected to Release Quarterly Earnings on ThursdayApyx Medical is expected to release Q3 2026 earnings on Thursday, November 5th, with analysts projecting a loss of $0.07 per share and revenue of $13.29 million. The company's last quarterly report showed EPS of -$0.07 and revenue of $13.88 million, beating estimates. Analysts have an average rating of Moderate Buy with a price target of $6.50.American Banking and Market NewsApyx Medical Corporation (NASDAQ:APYX) Stock Now Rated “Moderate Buy” by Sell-Side BrokeragesApyx Medical shares received an average "Moderate Buy" rating from eight brokerages, with a $6.50 price target. The company reported Q2 EPS of -$0.07, beating estimates, and revenue of $13.88 million. Analysts predict a fiscal-year EPS of -$0.25.